Panavance Therapeutics
Our Science
Pipeline
About GP-2250
About
About Panavance
Leadership
Board of Directors
Advisors & Collaborators
Contact Panavance
Resources
Publications
Brochures
Videos
Press Releases
Events
Participate
Let’s engage
.
Metabolism-based GP-2250 in combination with gemcitabine as a novel approach to pancreatic cancer: A mouse xenograft study- in vitro and in vivo. MBC Cancer
April 13, 2022
/
0 Minute Read